Bio-IT World March 26, 2025
Arbor Biotechnologies will advance its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system; Ataraxis AI will further the development of Ataraxis Breast, the world’s first AI-native prognostic/predictive platform for breast cancer; and more.
$350.7M: Series D for PARP1 Trials
Eikon Therapeutics announced the initial closing of a $350.7 million Series D financing to advance its pipeline and clinical-stage programs. Eikon’s lead program EIK1001 is a systemically administered co-agonist of toll-like receptors 7 and 8 currently in a Phase III trial for advanced melanoma. Eikon is also advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic...
Today's Sponsors
Today's Sponsor